Answers are grounded in this paper and cite their sources.
A live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine was evaluated in healthy respiratory syncytial virus/parainfluenza virus type 3 seropositive children aged 1 to 9 years. Three cohorts of 40 children were randomized 1:1 to receive 10, 10, or 10 median tissue culture infectious dose50 MEDI-534 vaccine or placebo. The vaccine's safety profile was similar to placebo, no viral shedding was detected, and the vaccine was minimally immunogenic.
No takes yet. Share an insight, caveat, or question.
Gomez et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: